Phase II Study of R-FND Followed by Radioimmunotherapy and R Maintenance for High-Risk FL


Phase II Study of R-FND Followed by Radioimmunotherapy and R Maintenance for High-Risk FL
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Stephanie A Gregory, MD (1/11/12)

Fowler NH et al. Phase II study with R-FND followed by 90-Y ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance for untreated high-risk follicular lymphoma. Proc ASH 2011;Abstract 99.

Dr Gregory is the Elodia Kehm Chair of Hematology, Professor of Medicine and Director of the Hematology Section at Rush University Medical Center in Chicago, Illinois.